CHINA LIFE

China Life’s 35 billion CNY state‑backed capital injection boosts solvency, governance and dividend growth, positioning the insurer for resilient expansion and stronger market confidence.

China Life’s patient capital strategy fuels hard‑tech growth—investing in X‑ray tube tech and semiconductors, boosting returns while supporting China’s industrial shift.